JoanneMarieDonovanMDPhD

Gastroenterology • Boston, MA

Associate Clinical Professor of Medicine, Harvard Medical School; Boston VA, VFW Parkway WestRox

Join to view full profile

Dr. Donovan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Donovan's full profile

Already have an account?

Office
150 South Huntington Avenue
Boston, MA 02130
Phone+1 617-323-7700

Education & Training

Brigham and Women's HospitalFellowship, Gastroenterology, 1989 - 1990
Brigham and Women's HospitalResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984

Certifications & Licensure

MA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Publications & Presentations

PubMed

Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent
Maria Cecilia Mancini, Gigi Shafai, Elizabeth Thaler, Joanne M. Donovan, Richard S. Finkel
Journal of Clinical Pharmacy and Therapeutics. 2021-07-14
18 citations
Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension...
Richard S. Finkel, Erika Finanger, Krista Vandenborne, H. Lee Sweeney, Gihan Tennekoon
Neuromuscular Disorders. 2021-02-04
16 citations
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD...
Richard S. Finkel, Craig M. McDonald, H. Lee Sweeney, Erika Finanger, Erin Neil Knierbein
Journal of Neuromuscular Diseases. 2021-01-01

Press Mentions

Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)October 28th, 2022
EDG-5506 Shows Promise at Reducing Becker MD Muscle DamageOctober 20th, 2022
EDG-5506 Shows Promise at Reducing Becker MD Muscle DamageOctober 20th, 2022
Join now to see all

Grant Support

Pilot Study--Mechanisms Of Cytoprotection By Hydrophilic Bile SaltsNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998